GenSight Biologics Confirms 2nd Successful GMP Batch of LUME

15.11.2023 - Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system ...

Related Keywords

Paris , France General , France , Gensight Biologics , European Medicines Agency , Sofinnova Partners , Sight Biologics , Bridge Financing , Sight Biologic , Mitochondrial Targeting Sequence , Leber Hereditary Optic Neuropathy , Gensight Biologic , Institut De La Vision , Adeno Associated Virus , Medicines Agency , Process Performance Qualification , Good Manufacturing Practice , Marketing Authorisation Application , Biologics License Application , Gensight Biologics Stock ,